MED.00132 Autologous Adipose-derived Regenerative Cell Therapy

This policy addresses autologous adipose-derived regenerative cell therapy, which involves harvesting and reinjecting a person’s own fat-derived cells (unprocessed or minimally processed), including products prepared with devices such as Lipogems. Anthem considers this therapy investigational/experimental and not medically necessary for all indications, so it is not covered. This non-coverage applies across all conditions, body sites, and surgical specialties, regardless of processing method or device used.

"Autologous adipose-derived regenerative cell therapy is consideredinvestigational and not medically necessaryfor all indications."

Sign up to see full coverage criteria, indications, and limitations.